DURHAM, N.C., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform, today announced that Jeff Abbey, president and chief executive officer, will present at the 17th Annual BIO CEO & Investor Conference on Monday, February 9th, 2015, at 3:30 p.m. Eastern Time. Mr. Abbey will discuss the AGS-003 clinical development program, including the pivotal ADAPT phase 3 trial, as well as the AGS-004 program. The conference will be held at the Waldorf Astoria in New York, NY.
A live audio webcast of the presentation can be accessed via the Investors section of the Company’s website at www.argostherapeutics.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. A replay of the webcast will be available for 14 days following the presentation.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos’ most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The Company is also developing a second Arcelis®-based product candidate, AGS-004, for the treatment of HIV, currently being evaluated in a phase 2 clinical trial in combination with a latency reversing drug for HIV eradication in adult patients. For more information about Argos Therapeutics, visit www.argostherapeutics.com.
CONTACT: Media: Adam Daley Berry & Company Public Relations adaley@berrypr.com (212) 253-8881 Investors: Nancy Yu Burns McClellan nyu@burnsmc.com (212) 213-0006
Help employers find you! Check out all the jobs and post your resume.
